Alzheimer’s play­er gets $47M, a new name and a pair of mar­quee board mem­bers

Af­ter eight years work­ing on the fringes of Alzheimer’s drug de­vel­op­ment, the group op­er­at­ing Neu­roPhage has added a cou­ple of high-pro­file biotech play­ers in the Cam­bridge/Boston hub to the board, adopt­ed a new name and com­plet­ed a hefty $47 mil­lion Se­ries E round aimed at gain­ing proof-of-con­cept da­ta for a lead drug that will try to land a nov­el one-two punch against the dis­ease.

The new name is Proclara Bio­sciences. The mon­ey comes from Mérieux Développe­ment and a group of uniden­ti­fied high-net worth in­di­vid­u­als and the ex­ecs are Third Rock’s Dan Lynch, the for­mer Im­clone chief who is tak­ing the ex­ec­u­tive chair­man’s role at Proclara, while chief blue­bird and Third Rock co-founder Nick Leschly al­so steps on to the board. Third Rock it­self is not in­volved with this syn­di­cate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.